Cancers, Vol. 14, Pages 565: Characteristics and Outcome of Elderly Patients ( & gt;55 years) with Acute Lymphoblastic Leukemia

Cancers, Vol. 14, Pages 565: Characteristics and Outcome of Elderly Patients (>55 years) with Acute Lymphoblastic Leukemia Cancers doi: 10.3390/cancers14030565 Authors: Daniela V. Wenge Klaus Wethmar Corinna A. Klar Hedwig Kolve Tim Sauer Linus Angenendt Georg Evers Simon Call Andrea Kerkhoff Cyrus Khandanpour Torsten Kessler Rolf Mesters Christoph Schliemann Jan-Henrik Mikesch Christian Reicherts Monika Brüggemann Wolfgang E. Berdel Georg Lenz Matthias Stelljes Prognosis of elderly ALL patients remains dismal. Here, we retrospectively analyzed the course of 93 patients >55 years with B-precursor (n = 88) or T-ALL (n = 5), who received age-adapted, pediatric-inspired chemotherapy regimens at our center between May 2003 and October 2020. The median age at diagnosis was 65.7 years, and surviving patients had a median follow-up of 3.7 years. CR after induction therapy was documented in 76.5%, while the rate of treatment-related death within 100 days was 6.4%. The OS of the entire cohort at 1 and 3 year(s) was 75.2% (95% CI: 66.4–84.0%) and 47.3% (95% CI: 36.8–57.7%), respectively, while the EFS at 1 and 3 years(s) was 59.0% (95% CI: 48.9–69.0%) and 32.9% (95% CI: 23.0–42.8%), respectively. At 3 years, the cumulative incidence (CI) of relapse was 48.3% (95% CI: 38.9–59.9%), and the CI rate of death in CR was 17.3% (95% CI: 10.9–27.5%)....
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research